Cosmos Health Secures 25M Unit Orderbook, Projects Over $10M Annual Profit
COSM•Cosmos Health’s Cana Laboratories has secured an orderbook over 25 million units through contracts up to ten years, spanning nine therapeutic categories. The 54,000-sq.-ft. EU-GMP and EMA-certified Athens facility—upgraded with $5.5 million and a new ACG capsule line—is positioned to generate over $10 million in recurring annual profit.
1. Orderbook and Contracts
Cana Laboratories has secured cumulative orders exceeding 25 million units under multi-year agreements up to ten years, diversified across nine therapeutic categories including CNS, musculoskeletal, dermatology, vitamins, oncology-support, women’s health, antiseptic, and wellness. Key partners include Provident Pharmaceuticals, Pharmex S.A., Verisfield S.A., Medical Pharmaquality, and Humacology.
2. Facility Upgrade and Capacity
The 54,000-sq.-ft. Athens facility is EU-GMP-licensed and EMA-certified for manufacturing pharmaceuticals, food supplements, cosmetics, biocides, and medical devices. A $5.5 million upgrade program installed new machinery, IT infrastructure, quality management systems, and a state-of-the-art ACG capsule-filling line to boost production capabilities.
3. Profit Outlook
At full capacity, the contract manufacturing division is expected to generate over $10 million in recurring annual profit. Cosmos Health plans to pursue further contracts and evaluate additional expansions to maximize high-margin, recurring-revenue growth within its vertically integrated model.
